Published in Medchemcomm on March 03, 2011
Lysophosphatidic acid is a modulator of cyst growth in autosomal dominant polycystic kidney disease. Cell Physiol Biochem (2011) 0.83
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med (2007) 5.06
Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell (1989) 4.88
LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol (2010) 3.91
Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem (2002) 3.53
Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol (2003) 2.43
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev (2010) 2.10
Dehydration of a phosphonate substrate analogue by glycerol 3-phosphate dehydrogenase. Biochem J (1974) 1.80
Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem (2005) 1.40
Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res (2008) 1.20
Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem (2003) 1.11
Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett (2004) 1.11
Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J Biol Chem (2000) 1.10
Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis (2008) 1.05
Phosphate isosteres in medicinal chemistry. Curr Med Chem (2005) 1.02
A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist. Bioorg Med Chem Lett (2004) 1.01
Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine. Mol Pain (2010) 1.00
Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett (2004) 0.93
Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors. J Med Chem (2006) 0.91
Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am J Physiol (1997) 0.90
Characterization of a receptor subtype-selective lysophosphatidic acid mimetic. Mol Pharmacol (1998) 0.87
Antihypertensive effect of an isolated phospholipid. Am J Physiol (1968) 0.82
The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem (2002) 6.96
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem (2007) 3.07
International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev (2002) 2.75
Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem (2004) 2.63
Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med (2010) 2.40
Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol (2006) 2.39
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev (2010) 2.10
Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem (2005) 1.84
Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res (2006) 1.81
FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol (2002) 1.79
Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem (2006) 1.70
Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res (2008) 1.51
Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem J (2009) 1.38
Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol (2008) 1.37
Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity. ChemMedChem (2010) 1.33
What makes the bioactive lipids phosphatidic acid and lysophosphatidic acid so special? Biochemistry (2005) 1.33
Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol (2010) 1.31
Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem (2010) 1.28
Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol (2005) 1.26
The N terminus of the human alpha1D-adrenergic receptor prevents cell surface expression. J Pharmacol Exp Ther (2004) 1.23
Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist. J Med Chem (2007) 1.22
Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem (2011) 1.21
Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem (2003) 1.11
Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett (2004) 1.11
S-nitrosothiol depletion in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2006) 1.11
Brown recluse spider (Loxosceles reclusa) venom phospholipase D (PLD) generates lysophosphatidic acid (LPA). Biochem J (2005) 1.10
Nutrient isothiocyanates covalently modify and inhibit the inflammatory cytokine macrophage migration inhibitory factor (MIF). Biochem J (2009) 1.09
Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis. Proc Natl Acad Sci U S A (2013) 1.08
Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem J (2012) 1.08
Novel human G-protein-coupled receptors. Biochem Biophys Res Commun (2003) 1.08
Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol (2004) 1.08
S1P/S1P1 signaling stimulates cell migration and invasion in Wilms tumor. Cancer Lett (2009) 1.08
Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int (2008) 1.07
Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett (2008) 1.07
Inhibition of human airway smooth muscle cell proliferation by beta 2-adrenergic receptors and cAMP is PKA independent: evidence for EPAC involvement. Am J Physiol Lung Cell Mol Physiol (2007) 1.07
Synthesis of para-alkyl aryl amide analogues of sphingosine-1-phosphate: discovery of potent S1P receptor agonists. Bioorg Med Chem Lett (2003) 1.06
Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2. Mol Cancer Res (2008) 1.06
Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis (2008) 1.05
FTY720 promotes local microvascular network formation and regeneration of cranial bone defects. Tissue Eng Part A (2010) 1.04
Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model. Antimicrob Agents Chemother (2012) 1.03
Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors. Bioorg Med Chem (2011) 1.03
Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists. Bioorg Med Chem Lett (2005) 1.02
In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity. Chem Res Toxicol (2008) 1.02
Synthesis of benzimidazole based analogues of sphingosine-1-phosphate: discovery of potent, subtype-selective S1P4 receptor agonists. Bioorg Med Chem Lett (2004) 1.02
A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist. Bioorg Med Chem Lett (2004) 1.01
Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog (2009) 1.00
Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochem J (2011) 0.99
Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines. J Med Chem (2002) 0.98
Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion. Biochem Pharmacol (2013) 0.97
Sphingosine-1-phosphate reduces CD4+ T-cell activation in type 1 diabetes through regulation of hypoxia-inducible factor short isoform I.1 and CD69. Diabetes (2007) 0.97
A rapid assay for assessment of sphingosine kinase inhibitors and substrates. Anal Biochem (2011) 0.97
Selective activation of sphingosine 1-phosphate receptors 1 and 3 promotes local microvascular network growth. Tissue Eng Part A (2010) 0.96
The isothiocyanate class of bioactive nutrients covalently inhibit the MEKK1 protein kinase. BMC Cancer (2007) 0.96
Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. Bioorg Med Chem Lett (2007) 0.95
Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS. J Neurochem (2009) 0.94
Investigation into the structure-activity relationship of novel concentration dependent, dual action T-type calcium channel agonists/antagonists. Bioorg Med Chem (2005) 0.94
Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett (2004) 0.93
alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors. Bioorg Med Chem (2007) 0.93
Sphingosine 1-phosphate chemical biology. Biochim Biophys Acta (2008) 0.93
The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice. Clin Immunol (2003) 0.93
Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int (2011) 0.92
Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors. Bioorg Med Chem Lett (2005) 0.92
The pharmacology and regulation of T type calcium channels: new opportunities for unique therapeutics for cancer. Cell Calcium (2006) 0.92
Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am J Physiol Renal Physiol (2003) 0.92
Dendritic cell sphingosine 1-phosphate receptor-3 regulates Th1-Th2 polarity in kidney ischemia-reperfusion injury. J Immunol (2012) 0.91
Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations. J Pharmacol Exp Ther (2010) 0.91
Drugging sphingosine kinases. ACS Chem Biol (2014) 0.91
The G protein-coupled receptor GPR4 suppresses ERK activation in a ligand-independent manner. Biochemistry (2003) 0.90
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces. Antimicrob Agents Chemother (2010) 0.90